The upcoming report from Royalty Pharma (RPRX) is expected to reveal quarterly earnings of $0.96 per share, indicating a decline of 40$671.45 million, representing a decrease of 40.6% year over year. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Prior to a ...